End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8023 USD | -0.41% | -10.10% | -97.04% |
May. 21 | Earnings Flash (SBFM) SUNSHINE BIOPHARMA Posts Q1 Revenue $7.5M | MT |
May. 20 | Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 44.94M | Sales 2025 * | 100M | Capitalization | 798K |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
-80.2
x | P/E ratio 2025 * |
1.34
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.75% |
1 day | -7.89% | ||
1 week | -10.10% | ||
Current month | -8.31% | ||
1 month | -44.28% | ||
3 months | -86.65% | ||
6 months | -96.79% | ||
Current year | -97.04% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 0.8023 | -0.41% | 2,584,381 |
24-05-21 | 0.8056 | -17.80% | 5,870,688 |
24-05-20 | 0.98 | +5.38% | 4,038,734 |
24-05-17 | 0.93 | +4.49% | 4,037,246 |
24-05-16 | 0.89 | -0.27% | 2,794,731 |
End-of-day quote Nasdaq, May 21, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.04% | 798K | |
+38.48% | 723B | |
+34.28% | 595B | |
-4.44% | 369B | |
+20.09% | 332B | |
+2.26% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.05% | 168B |
- Stock Market
- Equities
- SBFM Stock